When stratified by joint tumor receptor status, there was a significant positive association between urinary cadmium and ER+/PR+/HER2− breast cancer: The OR per category increase was 1.43 (95% CI: 1.18–1.73) (p-trend < 0.001), with a suggestion that this differed from the urinary cadmium and ER−/PR−/HER2+ breast cancer association (p-heterogeneity = 0.05) (Table 2). This evidence concerns the gene ERBB2 and breast cancer.